Conv. Plasma
Nigella Sativa
Peg.. Lambda

All molnupiravir studies
Meta analysis
Home COVID-19 treatment researchMolnupiravirMolnupiravir (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality 39% Improvement Relative Risk Ventilation 5% Hospitalization time -1% Molnupiravir  Flisiak et al.  EARLY TREATMENT Is early treatment with molnupiravir beneficial for COVID-19? Retrospective 590 patients in Poland (January - April 2022) Lower mortality with molnupiravir (p=0.034) Flisiak et al., Pharmacological Reports, Jul 2022 Favors molnupiravir Favors control

Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance

Flisiak et al., Pharmacological Reports, doi:10.1007/s43440-022-00408-6 (date from preprint)
Jul 2022  
  Source   PDF   All Studies   Meta AnalysisMeta
Retrospective 590 patients in Poland, 203 treated with mulnupiravir, showing lower mortality with treatment.
Concerns have been raised that the mutagenic mechanism of action may create dangerous variants or cause cancer Hadj Hassine, Huntsman, Marikawa, Swanstrom, Waters, Zibat. Multiple analyses have identifed variants potentially created by molnupiravir Fountain-Jones, Sanderson,
risk of death, 39.5% lower, RR 0.61, p = 0.03, treatment 20 of 203 (9.9%), control 63 of 387 (16.3%), NNT 16.
risk of mechanical ventilation, 4.7% lower, RR 0.95, p = 1.00, treatment 7 of 203 (3.4%), control 14 of 387 (3.6%), NNT 591.
hospitalization time, 0.9% higher, relative time 1.01, p = 0.96, treatment mean 11.6 (±7.9) n=203, control mean 11.5 (±9.3) n=387.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Flisiak et al., 6 Jul 2022, retrospective, Poland, peer-reviewed, 13 authors, study period 1 January, 2022 - 30 April, 2022.
All Studies   All Outcomes   Submit Updates or Corrections
This PaperMolnupiravirAll
Real-world experience with molnupiravir during the period of SARS-CoV-2 Omicron variant dominance
Robert Flisiak, Dorota Zarębska-Michaluk, Magdalena Rogalska, Justyna Anna Kryńska, Justyna Kowalska, Ewa Dutkiewicz, Krystyna Dobrowolska, Jerzy Jaroszewicz, Anna Moniuszko-Malinowska, Marta Rorat, Regina Podlasin, Olga Tronina, Piotr Rzymski
Pharmacological Reports, doi:10.1007/s43440-022-00408-6
Background The real-world effectiveness of molnupiravir (MOL) during the dominance of Omicron SARS-CoV-2 lineage is urgently needed since the available data relate to the period of circulation of other viral variants. Therefore, this study assessed the efficacy of MOL in patients hospitalized for COVID-19 in a real-world clinical practice during the wave of Omicron infections. Methods Among 11,822 patients hospitalized after 1 March 2020 and included in the SARSTer national database, 590 were treated between 1 January and 31 April 2022, a period of dominance of the Omicron SARS-CoV-2 variant. MOL was administered to 203 patients, whereas 387 did not receive any antiviral regimen. Both groups were similar in terms of sex, BMI and age allowing for direct comparisons. Results Patients who did not receive antiviral therapy significantly more often required the use of Dexamethasone and Baricitinib. Treatment with MOL resulted in a statistically significant reduction in mortality during the 28-day follow-up (9.9 vs. 16.3%), which was particularly evident in the population of patients over 80 years of age treated in the first 5 days of the disease (14.6 vs. 35.2%). MOL therapy did not affect the frequency of the need for mechanical ventilation, but patients treated with MOL required oxygen supplementation less frequently than those without antivirals (31.7 vs. 49.2%). The time of hospitalization did not differ between groups. Conclusions The use of molnupiravir in patients hospitalized for COVID-19 during the dominance of Omicron variant reduced mortality. This effect is particularly evident in patients over 80 years of age.
Arribas, Bhagani, Lobo, Khaertynova, Mateu et al., Randomized trial of molnupiravir or placebo in patients hospitalized with covid-19, NEJM Evid, doi:10.1056/evidoa2100044
Flisiak, Horban, Jaroszewicz, Kozielewicz, Mastalerz-Migas et al., Diagnosis and therapy of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of November 12, 2021. Annex no. 1 to the Recommendations of April 26, 2021, Pol Arch Intern Med, doi:10.20452/pamw.16140
Flisiak, Horban, Jaroszewicz, Kozielewicz, Mastalerz-Migas et al., Management of SARS-CoV-2 infection: recommendations of the Polish Association of Epidemiologists and Infectiologists as of February 23, Pol Arch Intern Med, doi:10.20452/pamw.16230
Flisiak, Zarębska-Michaluk, Berkan-Kawińska, Tudrujek-Zdunek, Rogalska et al., Remdesivir-based therapy improved the recovery of patients with COVID-19 in the multicenter, real-world SARSTer study, Pol Arch Intern Med
Gordon, Tchesnokov, Schinazi, Götte, Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template, J Biol Chem
Jayk, Da Silva, Musungaie, Kovalchuk, Gonzalez et al., Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients, N Engl J Med
Kumarasamy, Jindal, Saha, Singh, Rodduturi et al., Phase III trial of molnupiravir in adults with mild SARS-cov2 infection in India
Mader, Tydykov, Glück, Bertok, Weidlich et al., Omicron's binding to sotrovimab, casirivimab, imdevimab, CR3022, and sera from previously infected or vaccinated individuals, IScience
Painter, Natchus, Cohen, Holman, Painter, Developing a direct acting, orally available antiviral agent in a pandemic: the evolution of molnupiravir as a potential treatment for COVID-19, Curr Opin Virol
Rahmah, Abarikwu, Arero, Jibril, Fal et al., Oral antiviral treatments for COVID-19: opportunities and challenges, Rep: Pharmacol, doi:10.1007/s43440-022-00388-7
Vangeel, Chiu, Jonghe, Maes, Slechten et al., Remdesivir, molnupiravir and nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern, Antiviral Res
Wahl, Gralinski, Johnson, Yao, Kovarova et al., SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801, Nature
Wong, Au, Lau, Lau, Cowling et al., Real-world effectiveness of molnupiravir and nirmatrelvir/ ritonavir among COVID-19 inpatients during Hong Kong's Omicron BA.2 wave: an observational study, doi:10.1101/2022.05.19.22275291
Zarębska-Michaluk, Jaroszewicz, Rogalska, Martonik, Pabjan et al., Effectiveness of tocilizumab with and without dexamethasone in patients with severe COVID-19: a retrospective study, J Inflamm Res
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop